CKR-5 Antibody (R-C10): sc-57072

CKR-5 Antibody (R-C10) is a mouse monoclonal IgG1 antibody that detects CKR-5 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). CKR-5, a member of the C-C chemokine receptor family, plays a crucial role in the immune response by acting as a receptor for various chemokines, which are essential for the chemotaxis of immune cells such as T cells and monocytes to sites of inflammation. Notably, CKR-5 serves as a coreceptor for HIV, facilitating viral entry into host cells alongside CD4. This interaction highlights CKR-5′s dual role in both immune signaling and viral pathogenesis, making CKR-5 a critical target for therapeutic interventions aimed at HIV. CKR-5′s association with macrophage-tropic strains of HIV-1 underscores CKR-5′s importance in understanding the mechanisms of viral infection and the immune response, providing valuable insights for the development of antiviral strategies. Anti-CKR-5 antibody (R-C10) serves as an essential tool for researchers investigating the complexities of immune cell signaling and viral interactions, enabling the exploration of new avenues for treatment and prevention.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CKR-5 Antibody (R-C10) References:

1. Annulus fibrosus cells express and utilize C-C chemokine receptor 5 (CCR5) for migration.  |  Liu, W., et al. 2017. Spine J. 17: 720-726. PMID: 28108404
2. Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells.  |  Zi, J., et al. 2017. Am J Cancer Res. 7: 869-880. PMID: 28469959
3. Regulation of C-C chemokine receptor 5 (CCR5) stability by Lys197 and by transmembrane protein aptamers that target it for lysosomal degradation.  |  Petti, LM., et al. 2018. J Biol Chem. 293: 8787-8801. PMID: 29678881
4. C-C chemokine receptor type 5 links COVID-19, rheumatoid arthritis, and Hydroxychloroquine: in silico analysis.  |  Hachim, MY., et al. 2020. Transl Med Commun. 5: 14. PMID: 32923679
5. CCR5 is a potential therapeutic target for cancer.  |  Hemmatazad, H. and Berger, MD. 2021. Expert Opin Ther Targets. 25: 311-327. PMID: 33719836
6. Microglial cytokines poison neuronal autophagy via CCR5, a druggable target.  |  Festa, BP., et al. 2024. Autophagy. 20: 949-951. PMID: 37358357
7. The intricate role of CCL5/CCR5 axis in Alzheimer disease.  |  Ma, W., et al. 2023. J Neuropathol Exp Neurol. 82: 894-900. PMID: 37769321
8. Toxicogenomics of the C-C chemokine receptor type 5 (CCR5): Exploring the potential impacts of chemical-CCR5 interactions on inflammation and human health.  |  Ellwanger, JH. and Chies, JAB. 2024. Food Chem Toxicol. 186: 114511. PMID: 38360389
9. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.  |  Dudek, AM., et al. 2024. Cell Stem Cell. 31: 499-518.e6. PMID: 38579682
10. Host cell glycosylation selects for infection with CCR5- versus CXCR4-tropic HIV-1.  |  Itell, HL., et al. 2024. Nat Microbiol. 9: 2985-2996. PMID: 39363105

The preferred CKR-5 antibody is CKR-5 Antibody (D-6): sc-17833.